Key Takeaways
- Leucovorin, a prescription vitamin B9, was proposed as an autism spectrum disorder treatment.
- Scientific evidence supporting leucovorin's efficacy for autism is weak; some studies faced significant issues.
- Cerebral folate deficiency is a rare condition distinct from the vast majority of autism spectrum disorder cases.
- The pursuit of unproven autism treatments is fueled by market demand and anecdotal accounts, eroding trust in evidence-based medicine.
Deep Dive
- Leucovorin, a prescription form of vitamin B9 (folinic acid), was announced as a potential autism spectrum disorder treatment.
- It is distinct from over-the-counter folic acid supplements, which are widely available.
- Leucovorin is an FDA-approved drug already used for specific medical conditions.
- Leucovorin (folinic acid) is used to enhance chemotherapy effects, such as with 5-fluorouracil for colon cancer.
- It counteracts medications like methotrexate through a process known as leucovorin rescue.
- The drug is also approved for treating megaloblastic anemia, a condition caused by folate deficiency.
- Cerebral folate deficiency is a rare condition, with only approximately 20 documented cases, where antibodies block folate from entering the central nervous system.
- While folinic acid may assist a small subset of individuals with this deficiency, it does not impact the majority of those diagnosed with autism spectrum disorder.
- The scientific consensus indicates that missing cerebral folate deficiency diagnoses are not a significant factor in autism spectrum disorder.
- Dr. Oz extended an invitation to Dr. Richard Fry to announce leucovorin as a potential autism spectrum disorder treatment.
- Dr. Fry, a child neurologist and researcher, learned of the proposed announcement while in Saudi Arabia.
- This invitation brought leucovorin into public discussion regarding autism.
- Dr. Richard Fry, a child neurologist at Rosignol Medical Center, has researched leucovorin for two decades within functional medicine.
- He conducted five placebo-controlled studies on leucovorin for autism symptoms, with parents reporting observed improvements.
- A new, larger multi-center trial funded by the NIH is currently underway, with results pending.
- Dr. Fry authored 'The Folate Fix' and consults for Neuroneads, which markets a high-folate supplement.
- The supplement industry's complexity, particularly concerning folate forms and absorption, makes navigation difficult due to lack of FDA regulation.
- A central theory suggests all individuals with autism spectrum disorder have underlying mitochondrial dysfunction, possibly triggered by factors like vaccines.
- A 2006 case report co-authored by Dr. John Polling controversially linked a 6-year-old girl's autism and mitochondrial dysfunction to vaccines, resulting in a significant financial settlement.
- A 2012 study involving 93 individuals with autism spectrum disorder suggested a high prevalence of antibodies linked to cerebral folate deficiency.
- A subsequent 2018 double-blind, placebo-controlled trial with 48 children aged 3-13 reported positive outcomes, but faced significant criticism for methodological flaws and protocol changes.
- The FDA placed the 2018 study on hold in 2015 due to unreasonable risks and ultimately terminated the trial.
- Another study investigating a potential autism treatment had its NIH grant revoked due to disagreements, a lead investigator's departure, and data sharing issues.
- GlaxoSmithKline plans to seek approval for leucovorin for cerebral folate deficiency, but does not mention autism spectrum disorder, indicating a lack of evidence for its use in autism.
- Experts question claims of 85% clinical benefits for cerebral folate deficiency, emphasizing that the condition does not equate to autism.
- A psychiatry professor criticized the evidence for leucovorin's FDA approval for cerebral folate deficiency as weak, noting diagnosis often requires spinal taps, not blood tests.
- No evidence suggests leucovorin effectively treats autism spectrum disorder, and its continued pursuit is linked to market potential, anecdotal evidence, and a desire for answers, characterized as "bad science."